Author correction: Quiescence and attenuated DNA damage response promote survival of esophageal cancer stem cells(J Cell Biochem. (2021) 122, 301–302, 10.1002/jcb.24228);Quiescence and attenuated DNA damage response promote survival of esophageal cancer stem cells

Journal of Cellular Biochemistry

Volumn 113, Issue 12, 2012, Pages 3643-3652

  Chen, Yulin ^a   Li, Dan ^a   Wang, Dapeng ^b   Liu, Xuefeng ^a   Yin, Ning ^b   Song, Yongmei ^a   Lu, Shih Hsin ^a   Ju, Zhenyu ^c   Zhan, Qimin ^a  

^a CANCER HOSPITAL   (China)

^b INSTITUTE OF RADIATION MEDICINE   (China)

^c HANGZHOU NORMAL UNIVERSITY   (China)

Author keywords

CANCER STEM CELLS; DNA DAMAGE RESPONSE; QUIESCENCE

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CELL DNA; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GADD45A PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; MYC PROTEIN; PROTEIN P27; RETINOBLASTOMA PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL ISOLATION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA DAMAGE; DNA DAMAGE RESPONSE; DNA REPAIR; ESOPHAGUS CANCER; FLOW CYTOMETRY; GENOTOXICITY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; ULTRAVIOLET RADIATION; UPREGULATION;

EID: 84867553620     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.29864     Document Type: Erratum

References (41)

1. Alarcon RM, Rupnow BA, Graeber TG, Knox SJ, Giaccia AJ,. 1996. Modulation of c-Myc activity and apoptosis in vivo. Cancer Res 56: 4315-4319.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF,. 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988.
3. Amin HM, McDonnell TJ, Ma Y, Lin Q, Fujio Y, Kunisada K, Leventaki V, Das P, Rassidakis GZ, Cutler C, Medeiros LJ, Lai R,. 2004. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 23: 5426-5434.
4. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN,. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
5. Blanpain C, Mohrin M, Sotiropoulou PA, Passegue E,. 2011. DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell 8: 16-29.
6. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC,. 2009. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4: 226-235.
7. Campisi J, d'Adda di Fagagna F,. 2007. Cellular senescence: When bad things happen to good cells. Nat Rev Mol Cell Biol 8: 729-740.
8. Cartwright P, McLean C, Sheppard A, Rivett D, Jones K, Dalton S,. 2005. LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Development 132: 885-896.
9. Dalerba P, Cho RW, Clarke MF,. 2007. Cancer stem cells: Models and concepts. Annu Rev Med 58: 267-284.
10. Dean M, Fojo T, Bates S,. 2005. Tumour stem cells and drug resistance. Nat Rev Cancer 5: 275-284.
11. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF,. 2009. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458: 780-783.
12. Elmore S,. 2007. Apoptosis: A review of programmed cell death. Toxicol Pathol 35: 495-516.
13. Fleming HE, Janzen V, Lo Celso C, Guo J, Leahy KM, Kronenberg HM, Scadden DT,. 2008. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell 2: 274-283.
14. Frank NY, Schatton T, Frank MH,. 2010. The therapeutic promise of the cancer stem cell concept. J Clin Invest 120: 41-50.
15. Guerra L, Albihn A, Tronnersjo S, Yan Q, Guidi R, Stenerlow B, Sterzenbach T, Josenhans C, Fox JG, Schauer DB, Thelestam M, Larsson LG, Henriksson M, Frisan T,. 2010. Myc is required for activation of the ATM-dependent checkpoints in response to DNA damage. PLoS ONE 5: e8924.
16. Gupta PB, Chaffer CL, Weinberg RA,. 2009. Cancer stem cells: Mirage or reality ? Nat Med 15: 1010-1012.
17. Huang D, Gao Q, Guo L, Zhang C, Jiang W, Li H, Wang J, Han X, Shi Y, Lu SH,. 2009. Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev 18: 465-473.
18. Ji J, Liu R, Tong T, Song Y, Jin S, Wu M, Zhan Q,. 2007. Gadd45a regulates beta-catenin distribution and maintains cell-cell adhesion/contact. Oncogene 26: 6396-6405.
19. Kastan MB, Bartek J,. 2004. Cell-cycle checkpoints and cancer. Nature 432: 316-323.
20. Kiuchi N, Nakajima K, Ichiba M, Fukada T, Narimatsu M, Mizuno K, Hibi M, Hirano T,. 1999. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J Exp Med 189: 63-73.
21. Levine AJ,. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323-331.
22. Li L, Clevers H,. 2010. Coexistence of quiescent and active adult stem cells in mammals. Science 327: 542-545.
23. Li H, Gao Q, Guo L, Lu SH,. 2011. The PTEN/PI3K/Akt pathway regulates stem-like cells in primary esophageal carcinoma cells. Cancer Biol Ther 11: 950-958.
24. Mandal PK, Blanpain C, Rossi DJ,. 2011. DNA damage response in adult stem cells: Pathways and consequences. Nat Rev Mol Cell Biol 12: 198-202.
25. Merchant AA, Matsui W,. 2010. Targeting HedgehogâA cancer stem cell pathway. Clin Cancer Res 16: 3130-3140.
26. Orford KW, Scadden DT,. 2008. Deconstructing stem cell self-renewal: Genetic insights into cell-cycle regulation. Nat Rev Genet 9: 115-128.
27. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, Miele L,. 2010. Targeting Notch to target cancer stem cells. Clin Cancer Res 16: 3141-3152.
28. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, Morrison SJ,. 2010. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18: 510-523.
29. Reya T, Morrison SJ, Clarke MF, Weissman IL,. 2001. Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
30. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M,. 2010. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583-594.
31. Rogulski K, Li Y, Rothermund K, Pu L, Watkins S, Yi F, Prochownik EV,. 2005. Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt-Mdm2-p53 pathway. Oncogene 24: 7524-7541.
32. Seton-Rogers S,. 2011. Cancer stem cells. VEGF promotes stemness. Nat Rev Cancer 11: 831.
33. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, Wong KK, Brandstetter K, Wittner B, Ramaswamy S, Classon M, Settleman J,. 2010. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69-680.
34. Vazquez A, Bond EE, Levine AJ, Bond GL,. 2008. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7: 979-987.
35. Vermeulen L, De Sousa EMF, van der Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H, Sprick MR, Kemper K, Richel DJ, Stassi G, Medema JP,. 2010. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12: 468-476.
36. Visvader JE, Lindeman GJ,. 2008. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
37. Vlashi E, McBride WH, Pajonk F,. 2009. Radiation responses of cancer stem cells. J Cell Biochem 108: 339-342.
38. Wang J, Guo LP, Chen LZ, Zeng YX, Lu SH,. 2007. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res 67: 3716-3724.
39. Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, Kim DW, Hofmann CS, Pianetti S, Romieu-Mourez R, Freedman LP, Sonenshein GE,. 2001. Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene 20: 1688-1702.
40. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E III, Zhang Y,. 2007. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 104: 16158-16163.
41. Zou P, Yoshihara H, Hosokawa K, Tai I, Shinmyozu K, Tsukahara F, Maru Y, Nakayama K, Nakayama KI, Suda T,. 2011. p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70. Cell Stem Cell 9: 247-261.